THE SCIENTIFIC DISCOURSE ON DUCHENNE MUSCULAR DYSTROPHY: MOLECULAR PATHOPHYSIOLOGY, GENETIC MECHANISMS, PHARMACOTHERAPEUTIC ADVANCES, PRECISION MEDICINE, EVIDENCE-BASED MEDICINE AND EMERGING MULTIDISCIPLINARY TREATMENT STRATEGIES

Abstract

Duchenne muscular dystrophy (DMD) represents a severe, progressive, X-linked neuromuscular disorder characterized by profound skeletal and cardiac muscle degeneration, progressive loss of motor function, respiratory insufficiency, and substantial premature morbidity and mortality. The disease is primarily attributable to pathogenic variants in the DMD gene encoding dystrophin, a critical cytoskeletal protein that stabilizes the sarcolemmal membrane through its interaction with the dystrophin-associated glycoprotein complex. Disruption or complete absence of functional dystrophin induces sarcolemmal fragility, aberrant calcium influx, mitochondrial dysfunction, oxidative stress, inflammatory activation, necrotic myofiber degeneration, and progressive replacement of contractile tissue by fibrosis and adipose tissue. Consequently, DMD constitutes not only a paradigmatic monogenic disorder but also a complex translational model integrating molecular genetics, cellular pathophysiology, pharmacology, precision medicine, and multidisciplinary clinical management. The genetic architecture of DMD demonstrates substantial molecular heterogeneity, encompassing large deletions, duplications, small insertions or deletions, nonsense variants, splice-site abnormalities, and other pathogenic alterations. Contemporary molecular diagnostics, including next-generation sequencing, multiplex ligation-dependent probe amplification, and complementary genomic technologies, facilitate accurate variant characterization, genetic counseling, carrier identification, prenatal assessment, and therapeutic stratification. Importantly, genotype–phenotype relationships provide a mechanistic foundation for mutation-specific therapeutic interventions designed to restore dystrophin expression or ameliorate downstream molecular pathology. Pharmacotherapeutic management has historically relied on glucocorticoids, particularly prednisone, prednisolone, and deflazacort, which may prolong ambulation and attenuate functional decline but are associated with clinically significant adverse effects. The therapeutic landscape has subsequently expanded through exon-skipping strategies, mutation-directed molecular interventions, and dystrophin-restoration approaches, including antisense oligonucleotides and gene-transfer technologies. These innovations exemplify the transition from conventional symptomatic pharmacotherapy toward molecularly targeted therapeutics. Emerging gene therapy platforms employing micro-dystrophin constructs represent a particularly consequential development, although their clinical implementation requires rigorous assessment of durability, immunogenicity, safety, vector-associated limitations, and long-term therapeutic effectiveness. Evidence-based medicine provides an essential framework for evaluating these rapidly evolving interventions through systematic appraisal of randomized clinical trials, longitudinal cohort studies, natural-history investigations, biomarker research, and real-world evidence. Therapeutic decision-making increasingly requires integration of genetic diagnosis, age, ambulatory status, disease stage, comorbidities, treatment response, safety parameters, patient-centered outcomes, and individualized risk–benefit assessment. Precision medicine therefore represents a central paradigm for optimizing therapeutic selection and developing genotype-specific interventions while acknowledging substantial interindividual variability in disease progression and treatment response. Comprehensive DMD management extends beyond dystrophin restoration and pharmacological intervention. Evidence-based multidisciplinary care incorporates cardioprotective therapy, respiratory surveillance and assisted ventilation when indicated, orthopedic management, bone-health preservation, nutritional optimization, rehabilitation, physical and occupational therapy, psychosocial support, endocrinological monitoring, anesthetic planning, and structured transition from pediatric to adult healthcare. Cardiac surveillance is particularly important because dystrophin deficiency affects cardiomyocytes and may result in progressive cardiomyopathy and arrhythmogenic complications. Similarly, respiratory management remains fundamental because progressive respiratory muscle weakness contributes substantially to morbidity.The contemporary scientific discourse on DMD demonstrates a profound transformation from supportive management toward mechanism-based, genetically informed, and increasingly precision-oriented therapeutics. Integration of molecular pathophysiology, genomic medicine, pharmacology, evidence-based clinical practice, advanced gene and RNA technologies, and coordinated multidisciplinary care provides a comprehensive framework for improving functional outcomes, quality of life, and survival. Future research should prioritize durable dystrophin restoration, personalized therapeutic algorithms, combination strategies, validated molecular and functional biomarkers, equitable access to innovative therapies, and rigorous long-term pharmacovigilance. Such an integrated translational framework is essential for converting advances in molecular science into clinically meaningful and sustainable improvements for individuals affected by Duchenne muscular dystrophy.